Merck (@Merck) header
Merck (@Merck) profile picture

We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only. FLS: https://www.teapawt.org/t.co/QUXfCXVlx3

Rahway, NJ
Joined April 2009
Photo by Merck (@Merck)Photo by Merck (@Merck)Photo by Merck (@Merck)Photo by Merck (@Merck)Photo by Merck (@Merck)Photo by Merck (@Merck)Photo by Merck (@Merck)Photo by Merck (@Merck)Photo by Merck (@Merck)Photo by Merck (@Merck)
Learn more about our latest update in #hematology here: go.merck.com/~upd
1
7
3,058
Today, we announced a positive CHMP opinion recommending the approval of an option to help protect against respiratory syncytial virus (#RSV) in certain at-risk children up to 24 months of age. Learn more: go.merck.com/~5sp
3
5
1,256
Today, we announced a positive CHMP opinion for a potential new combination treatment for certain people with #KidneyCancer in the European Union. Read more: go.merck.com/~aa0
1
9
1,549
New Phase 2b data for an investigational therapy in adults with #MASH were presented today at #TLM2026 and published in The Lancet. Learn more about the findings and our ongoing research in this chronic, progressive liver disease: go.merck.com/~3a3
3
1
1
8
1,300
Today we announced the initiation of a phase 3 study for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients with a history of them. Learn more about the trial: go.merck.com/~n3w
4
2
6
1,436
We’re excited to be at #HIV Glasgow to share new #HIV data. Learn more: go.merck.com/~vnw
1
1
9
2,306
Join us today at 9 a.m. ET to learn more about our Q3 2026 #earnings: go.merck.com/~1bo $MRK
2
1
5
1,465
Our Q3 2026 #earnings results are live: go.merck.com/~hj7 Swipe below for perspective from Chairman and CEO Rob Davis. $MRK
1
10
1,453
Today, we presented late-breaking Phase 3 data in certain patients with advanced or recurrent #EndometrialCancer. We remain committed to advancing treatment options that can address unmet needs for those living with this disease. Learn more: go.merck.com/~82i
2
2
1
5
1,674
Today, we announced findings from our Phase 3 trial evaluating our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with endometrial cancer. The results were presented for the first time during a Presidential Symposium at ESMO. go.merck.com/~5wh
2
8
1,878
We announced positive Phase 3 data for our investigational individualized neoantigen therapy in combination with our company’s immunotherapy for patients with completely resected stage IIB-IV #melanoma in collaboration with @moderna_tx. Read more: go.merck.com/~km1
5
7
2
26
3,691
Today, the European Commission approved a combination regimen for adults with muscle-invasive #BladderCancer (MIBC). Learn more about how we're helping advance cancer care with Pfizer and Astellas: go.merck.com/~oa7
2
1
8
2,202
We’re presenting new data from our industry-leading #oncology pipeline and portfolio at this year’s ESMO Congress, including three presentations from pivotal Phase 3 trials in Presidential Symposia. Learn more about our commitment to advancing research across a range of cancer types: go.merck.com/~yuc
7
6
1
25
3,329
Today at #AAO2026, we’re presenting data from our Phase 2b/3 trial of an investigational drug in patients with diabetic macular edema (DME). Learn more: go.merck.com/~4ba
5
3
1
11
2,143
Today we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more: go.merck.com/~73c
15
3
16
5,497
Learn more about our latest update in #oncology: go.merck.com/~oolz4s
6
2
12
5,312
In collaboration with @EisaiUS, we’re proud to announce today’s #FDA approval of a new combination treatment option for certain patients with advanced renal cell carcinoma, marking an important step forward for people living with #KidneyCancer. Learn more: go.merck.com/~nex
10
6
1
22
6,471
Today, we announced Phase 2b/3 topline results for our investigational therapy in patients with #DiabeticMacularEdema (DME). This important milestone reflects our ongoing commitment to advancing research in #ophthalmology. Learn more: go.merck.com/~k7a
4
2
18
3,886
Today, the FDA approved an updated label for a treatment option for adults living with pulmonary arterial hypertension (#PAH). Read more: go.merck.com/~c9i
2
2
8
2,399
Learn more about our latest update in #oncology: go.merck.com/~yhzw
1
1
7
3,292